Pharmaceutical

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.

Apr 27, 2024 - 00:00
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.
Read the original article

Tags:

Previous Article

The privileged status of orphan medicines in Germany

Next Article

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Roche relaunches refillable wet AMD implant two years after recall

Roche relaunches refillable wet AMD implant two years a...

Jul 10, 2024

Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns

Donanemab: FDA AdCom will put spotlight on tau enrolmen...

Mar 22, 2024

Galapagos enters deal to boost decentralised CAR-T therapy production

Galapagos enters deal to boost decentralised CAR-T ther...

May 19, 2024